Quote of the Day from Tower Hill Tube station a couple of years ago is rather apt when comparing different cancer therapies

Every novel cancer immunotherapy has its day in the limelight, although it obviously goes without saying we shouldn’t compare them unless in a head-to-head trial.

What if the comparisons are made using the wrong parameters, however?

Well, this just compounds the problem further and does neither product nor company or researchers any justice.

This time around we continue the latest chapter in an story we have been following for several years now before it was really in many people’s conscience.

Sometimes it helps to go back to the beginning to see how far things have come, other times it is more useful to look in a broader context of the space it is competing in.

In this latest installment we attempt a look at both plus offer some commentary on how it could be viewed…


To learn more about the latest immunotherapy data and get a heads up on our oncology commentary and insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by